Neurosearch A/S (NEUR.CO) Announces Changes In The Executive Board And Board Of Directors And Informs Of An EGM

As announced in late July 2013, René Schneider will resign from the position as CEO of NeuroSearch A/S (NEUR) as of 30 November 2013. The Board of Directors has decided to appoint the present Chairman of the Board of Directors, Allan Andersen, as new CEO as of 1 December 2013. It is agreed, until further notice, that the position will be a part-time position. After careful consideration, the Board of Directors has concluded that this solution will be the best way to safeguard the interests of the company in a financially sound manner in the coming period when the company's freedom of action will be restricted due to the coming criminal proceedings resulting from the indictment in July 2013 by the Public Prosecutor for Serious Economic and International Crime, see for example the recent 3rd quarter interim financial report.

Also, as from the same date the Board of Directors has decided to provisionally appoint Christian Lundgren as Chairman of the Board of Directors.

Torbjörn Bjerke has given notice that he wishes to resign from the Board of Directors. Furthermore, the employee-elected board member Morten Nielsen will resign from the Board of Directors at the end of November 2013 due to termination of his employment with the company.

Tomorrow, an extraordinary general meeting will be summoned to elect a new member of the Board of Directors. No new member will be elected for Morten Nielsen's seat on the Board of Directors. The extraordinary general meeting will be held on Monday, 9 December 2013. Consequently, in the period until the extraordinary general meeting, the Board of Directors will consist of Christian Lundgren, Torbjörn Bjerke and Allan Andersen.

Allan Andersen
Chairman of the Board of Directors

Contacts
René Schneider, CEO, telephone: +45 2911 2097

Allan Andersen, Chairman of the Board of Directors, telephone: +45 4016 3864

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.